Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis.
Eight patients with active toxoplasmic retinochoroiditis were treated with clindamycin and a triple sulphonamide combination for a period of up to 6 weeks. In addition systemic prednisone was administered when the optic nerve or the macula was involved (6 of the 8 cases). In all cases we observed clinical improvement within 2 weeks. Visual acuity improved in all cases. Side effects of the treatment were observed in 2 cases. The follow-up period ranged from 8 to 22 months.
D000293:Adolescent; D000328:Adult; D002648:Child; D002981:Clindamycin / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D012008:Recurrence; D013411:Sulfadiazine / Q000627:therapeutic use; D013418:Sulfamethazine / Q000627:therapeutic use; D013424:Sulfanilamides / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014126:Toxoplasmosis, Ocular / Q000188:drug therapy*; D014792:Visual Acuity
D004338:Drug Combinations; D013424:Sulfanilamides; D013449:Sulfonamides; D013411:Sulfadiazine; D002981:Clindamycin; D013418:Sulfamethazine; D011241:Prednisone; C009348:sulfanilylurea